Chang Gung, MSD to set up research center The China Post news staff May 19, 2013, 12:11 am TWNTAIPEI, Taiwan -- Chang Gung Memorial Hospital (CGMH) and U.S.-based Merck Sharp & Dohme (MSD) have signed a memorandum of understanding (MOU) for jointly setting up a clinical research center. The center will focus on clinical drug research for hepatitis C as well as neurological and respiratory diseases, CGMH said.The MOU was signed by officials from both sides at a ceremony in Taipei on May 16, including: Weng Wen-neng, head of CGMH; and Peter Wright, who heads MSD's Global Clinical Trial Operations in Asia.CGMH, a leading medical center in Taiwan, started building up its clinical trial center in November 2009. So far, it has conducted clinical trials on 310 new drugs, CGMH said.It also noted that Chang Gung medical teams have been playing leading roles in many clinical drug trials.Weng stressed that the collaboration with MSD is meant to meet the medical needs of Taiwan's people, as well as promote Taiwan's clinical research achievements on the international stage.MSD said it has increased its investments in Taiwan for clinical trials on new drugs. It said it has conducted clinical trials on more than 200 new drugs over the last five years, and its investment in Taiwan so far has exceeded NT$800 million.Currently, CGMH and MSD are co-conducting clinical trials on 30 new drugs, including ones targeting diabetes, heart disease and cancer. Both sides have been cooperating on clinical drug trials for over 15 years, MSD said.
No comments:
Post a Comment